Satyadeva Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 02-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 02-07-2024
- Company Age 24 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.10 Cr
as on 02-07-2024
- Satisfied Charges ₹ 39.65 Cr
as on 02-07-2024
- Revenue -0.86%
(FY 2023)
- Profit -49.81%
(FY 2023)
- Ebitda -357.43%
(FY 2023)
- Net Worth 2.27%
(FY 2023)
- Total Assets 11.87%
(FY 2023)
About Satyadeva Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹7.10 Cr. The company has closed loans amounting to ₹39.65 Cr, as per Ministry of Corporate Affairs (MCA) records.
Swathi Nandamuri, Venkata Averineni, Srinivasa Tubati, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239TG2000PTC035107
- Company No.
035107
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Aug 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Satyadeva Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Eswara Kosaraju  | Managing Director | 11-Aug-2000 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Swathi Nandamuri | Director | 01-Apr-2019 | Current |
| Venkata Averineni | Whole-Time Director | 21-Jul-2005 | Current |
| Srinivasa Tubati | Whole-Time Director | 21-Jul-2005 | Current |
| Hari Kosaraju | Director | 01-Apr-2019 | Current |
Financial Performance of Satyadeva Pharmaceuticals.
Satyadeva Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.86% decrease. The company also saw a substantial fall in profitability, with a 49.81% decrease in profit. The company's net worth moved up by a moderate rise of 2.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satyadeva Pharmaceuticals?
In 2023, Satyadeva Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 23 Jun 2016 | ₹7.10 Cr | Open |
Hdfc Bank Limited Creation Date: 30 Oct 2017 | ₹18.00 Cr | Satisfied |
Axis Bank Limited Creation Date: 22 Aug 2016 | ₹16.60 Cr | Satisfied |
How Many Employees Work at Satyadeva Pharmaceuticals?
Satyadeva Pharmaceuticals has a workforce of 149 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satyadeva Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satyadeva Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
